Zimmer Biomet Holdings, Inc.


SKU: ZBH-1 Category:


In the latest quarterly result, Zimmer managed on-par net sales amounted to $1.754 billion, reflecting a 5% increase on a reported basis, with a concurrent 4.7% rise when excluding the impact of foreign currency. GAAP diluted earnings per share in Q3 were $0.77, compared to $0.92 in the prior year. In terms of cash and liquidity, operating cash flows amounted to $338 million, with free cash flow at $189 million for the quarter. The balance sheet remained strong, closing with just under $300 million in cash and cash equivalents. Internationally, growth reached 2.9%, with more tempered results in Europe and Asia due to challenging comps and geopolitical factors. Global Knees demonstrated robust growth spurred by the Persona product portfolio’s continued adoption and the advantages of the ROSA robotics platform. Within the SET category, growth reached 2.8%, impacted by the selling day headwind. Key focus areas, including sports, upper extremities, and CMFT, posted double-digit growth, partially offset by other subsegments. Looking ahead, their team expects to increase full-year operating margins by about 100 basis points in a challenging environment. The expectations for interest and other nonoperating expenses, tax rate, and shares outstanding remain unchanged. Free cash flow for the year is expected to range between $950 million and $1 billion.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!